Provided by Tiger Trade Technology Pte. Ltd.

Avis Budget

126.11
-0.6299-0.50%
Volume:65.96K
Turnover:8.41M
Market Cap:4.45B
PE:-7.03
High:129.00
Open:126.24
Low:126.11
Close:126.74
52wk High:847.70
52wk Low:85.96
Shares:35.32M
Float Shares:14.85M
Volume Ratio:0.54
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.9408
EPS(LYR):-25.2557
ROE:5800.00%
ROA:2.70%
PB:-1.31
PE(LYR):-4.99

Loading ...

Avis Budget enters settlement agreement with Pentwater Capital Management

TIPRANKS
·
Jun 23

Movement Alert|Avis Budget Group Rises 6.83% in After-Hours Trading, Settlement Reached with Pentwater Capital Management

Market Focus
·
Jun 23

Avis Budget Group - Settlement Amount Set at $650 Mln in Cash - SEC Filing

THOMSON REUTERS
·
Jun 23

Avis Budget Group - Enters Settlement Agreement With Pentwater Capital Management on June 19, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 23

Avis Budget reaches USD 650 million settlement with Pentwater in short-swing profits lawsuit

Reuters
·
Jun 23

CARsgen Wins First-Ever Global Approval for Solid-Tumor CAR T Therapy in China

TIPRANKS
·
Jun 22

CARSGEN-B Receives NMPA Approval for Claudin18.2 CAR-T Therapy Kelimei®

Stock News
·
Jun 22

Hong Kong Shares Surge as CARSGEN-B Achieves Landmark Approval for First Solid Tumor CAR-T Therapy

Stock News
·
Jun 22

How Early Allogeneic CAR T Results At CARsgen (SEHK:2171) Have Changed Its Investment Story

Simply Wall St.
·
Jun 19

Movement Alert|Avis Budget Group Rises 5.32% in Regular Trading, Trading at $189.8

Market Focus
·
Jun 19

Bristol Myers Squibb (BMY) Reports Strong Myeloma Trial Results And Early CAR T Progress

Simply Wall St.
·
Jun 18

CARsgen Therapeutics Holdings (SEHK:2171) Stock Looks Rich Even After New CAR T Data

Simply Wall St.
·
Jun 16

Legend Biotech Unveils Strong First-in-Human Data for In Vivo CAR-T LB2501 at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma

MT Newswires Live
·
Jun 15

Park24 to Reintroduce Shareholder Benefits Tied to Times CAR Service

TIPRANKS
·
Jun 15

CARsgen Advances Allogeneic CAR T Programs After Positive Early Data at EHA 2026

TIPRANKS
·
Jun 15

Legend Biotech announces first clinical proof-of-concept data for LB2501

TIPRANKS
·
Jun 15

GenScript Associate Legend Biotech Reports Promising In Vivo CAR-T Data in B-Cell Lymphoma

TIPRANKS
·
Jun 14

Genscript Biotech's Affiliate Reports Proof of Concept for Novel In Vivo Dual-Target CAR-T Therapy in Lymphoma

Stock News
·
Jun 14

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14